Iterum Therapeutics plc (ITRM)
2025-06-30 | ||||
|---|---|---|---|---|
| Income tax expense | 59 | |||
| Research and development | 1,000 | |||
| Cost of sales | 345 | |||
| General and administrative | 4,184 | |||
| Total operating expenses | 5,529 | |||
| Operating loss | -5,529 | |||
| Adjustments to fair value of derivatives | -585 | |||
| Other expense, net | -20 | |||
| Interest expense, net | -316 | |||
| Total other expense | -921 | |||
| Loss before income taxes | -6,450 | |||
| Net loss | -6,509 | |||
| Net loss per share - basic | -0.16 | |||
| Net loss per share - diluted | -0.16 | |||
| Weighted average number of shares outstanding, diluted | 39,935,213 | |||
| Weighted average ordinary shares outstanding - basic | 39,935,213 | |||